Unlocking the predictive potential of cancer organoids with AI-powered computer vision and data processing

Abraham Lin^{1,2}, Maxim Le Compte^{1,2}, Edgar Cardenas De La Hoz¹, Tyler Gilcrest¹, Christophe Deben^{1,2}

¹Orbits Oncology, San Francisco, USA


²Center for Oncological Research, University of Antwerp, Belgium



EARLY RESEARCH



CLINICAL TRIALS




Cells



Animals


"It's time to bring patient insights into early cancer drug discovery"



Patients

ADVANCED BIOLOGY

Patient-derived organoids are the most human-like cancer models



Organoids retain:

- Patient genetics
- Patient mutations
- Patient tumor architecture
- Patient diversity

Promising for novel drug research, but very difficult to analyze


ADVANCED IMAGE ANALYSIS

Al-powered digital platform to extract therapeutically relevant metrics from organoid imagery



CLINICAL INSIGHTS


Combining biology with AI enables precision cancer drug discovery



Understand
Drug Mechanism



Predict
Patient Response




IdentifyBiomarkers



Automate Processes

ORBITS ONCOLOGY ANALYSIS OUTPERFORMS INDUSTRY STANDARD



BETTER RESOLUTION

- Monitor lifecycle of organoids over time
- Analyze organoids at the single-organoid population level
- Quantify intratumoral heterogeneity and response to drugs
- Understand how novel drugs work

MORE INFORMATION

- Follow on LinkedIn
- Read our publications
- Watch our demo
- Visit our website




Contact us: Dr. Abraham Lin CEO, Orbits Oncology

abraham.lin@orbits-oncology.com

HIGHER CORRELATION TO PATIENT

- Predict patient response to novel drugs
- Identify potential for therapy resistance
- Select the best drugs to move into clinical trial
- Match the right drugs to the right patients





Orbits Oncology
3175 Hanover St
Palo Alto, CA, USA 94304
https://www.orbits-oncology.com/

Industry Engagements:









